Allogenica Secures €2.5 Million Grant to Advance Universal CAR-T Therapy and Strengthen France's Biotherapy Leadership
Allogenica Secures €2.5 Million Grant to Advance Universal CAR-T Therapy and Strengthen France's Biotherapy Leadership
Allogenica received a €2.5 million grant from the French government's France 2030 program to support the industrialization of its breakthrough universal CAR-T therapies for blood cancers.
Cost-effective, scalable CAR-T solutions: Allogenica, using its proprietary CAR-pre-T technology, reduces production costs by tenfold and enables large-scale production, enhancing treatment availability and making CAR-T therapy more accessible to patients globally.
With this funding, Allogenica will collaborate with strategic partners across the 100% French ecosystem to establish a cutting-edge CAR-T biomanufacturing by 2026, strengthening France's global leadership position and driving economic growth and job creation.
Lyon, France, March 19, 2025, Allogenica, an innovative biotechnology company developing next-generation universal CAR-T therapies for blood cancers, rare diseases, and autoimmune disorders, has been awarded a €2.5 million grant under the French government's "Innovations in Biotherapies and Bioproduction for France 2030" program. This prestigious funding will help accelerate the industrialization of Allogenica's lead-candidate CAR-T, called the XL-001, making them safer, more accessible, and cost-effective, primarily for patients with leukemia and lymphoma. This grant is part of a selective initiative, with Allogenica standing out as one of the few companies entrusted with this strategic support, underscoring its significant role in the biotherapy sector.
"This financing is an important milestone for Allogenica, validating our technology and accelerating our path to clinical application," said Dr. Inna Menkova, CEO of Allogenica. "By industrializing our universal CAR-T platform, we are not only expanding treatment options for patients but also reinforcing France's role as a global leader in biotherapy. We are grateful for the support of France 2030 and look forward to bringing life-saving therapies to patients around the world."
Transforming cancer therapies and seizing a growing market opportunity
CAR-T therapies have revolutionized cancer treatment, offering remission rates exceeding 90% for relapsed or refractory blood cancers. However, they have been limited by their reliance on patient-derived cells, resulting in high costs and manufacturing and logistic complexities. Allogenica overcomes these limitations with its universal CAR-T therapy, XL-001, which targets CD19-positive blood cancers. Using genetically modified immature T cells precursors (pre-T) derived from donor stem cells, XL-001 enables large-scale production and rapid patient access, reducing costs tenfold and significantly improving accessibility and sustainability.
The global CAR-T therapies ...
